Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Allergy Thera. (AGY) Share Price

Price 7.125p on 26-06-2025 at 12:34:25
Change -0.575p -7.47%
Buy 7.50p
Sell 6.75p
Buy / Sell AGY Shares
Last Trade: Sell 1,178.00 at 7.033p
Day's Volume: 1,231,931
Last Close: 7.70p
Open: 7.85p
ISIN: GB00B02LCQ05
Day's Range 7.125p - 7.85p
52wk Range: 3.88p - 7.85p
Market Capitalisation: £340m
VWAP: 7.315948p
Shares in Issue: 4,766m

Allergy Thera. (AGY) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 1,178 7.033p Ordinary
13:34:23 - 26-Jun-25
Buy* 50,000 7.275p Ordinary
12:33:54 - 26-Jun-25
Buy* 50,000 7.28p Ordinary
11:32:50 - 26-Jun-25
Buy* 80,000 7.30p Suspected BUY Trade
11:00:00 - 26-Jun-25
Unknown* 80,000 7.20p OTC Trade
10:54:37 - 26-Jun-25
Buy* 80,000 7.20p Ordinary
10:54:37 - 26-Jun-25
Buy* 20,000 7.30p Ordinary
10:50:59 - 26-Jun-25
Unknown* 20,000 7.30p OTC Trade
10:50:59 - 26-Jun-25
Buy* 6,698 7.30p Ordinary
10:29:01 - 26-Jun-25
Buy* 40,000 7.30p Ordinary
09:32:40 - 26-Jun-25
See more Allergy Thera. trades

Allergy Thera. (AGY) Share Price History

Time period:
to
Date Open High Low Close Volume
25th Jun 2025 (Wed) 7.15 7.70 7.00 7.70 386,719
24th Jun 2025 (Tue) 7.00 7.50 7.00 7.00 364,674
23rd Jun 2025 (Mon) 7.00 7.00 7.00 7.00 297,610
20th Jun 2025 (Fri) 7.05 7.35 6.90 6.90 294,361
19th Jun 2025 (Thu) 7.10 7.10 6.90 6.90 123,576
18th Jun 2025 (Wed) 7.10 7.10 7.00 7.00 761,218
17th Jun 2025 (Tue) 7.20 7.20 7.00 7.10 492,458
16th Jun 2025 (Mon) 7.40 7.50 7.00 7.50 140,300
13th Jun 2025 (Fri) 7.00 7.25 7.00 7.25 99,844
12th Jun 2025 (Thu) 7.00 7.30 6.60 6.60 147,784
11th Jun 2025 (Wed) 7.15 7.30 7.00 7.15 183,645
10th Jun 2025 (Tue) 7.30 7.30 7.00 7.00 29,120
9th Jun 2025 (Mon) 6.95 7.50 6.75 7.30 72,012
6th Jun 2025 (Fri) 6.80 7.45 6.70 6.80 40,798
5th Jun 2025 (Thu) 6.95 7.50 6.75 7.40 136,291
4th Jun 2025 (Wed) 6.95 7.50 6.75 6.80 197,082
3rd Jun 2025 (Tue) 6.95 7.45 6.90 6.90 56,364
2nd Jun 2025 (Mon) 7.25 7.25 6.80 6.80 420,675
30th May 2025 (Fri) 7.05 7.10 7.00 7.10 362,549
29th May 2025 (Thu) 7.35 7.35 6.90 6.90 511,409
28th May 2025 (Wed) 7.60 7.60 7.00 7.20 869,644
27th May 2025 (Tue) 7.50 7.50 7.00 7.45 387,794
26th May 2025 (Mon) 7.50 7.50 7.50 7.50 0
See more Allergy Thera. price history

Allergy Thera. (AGY) Share News

Allergy Therapeutics half-year loss narrows on lower expenses

31st Mar 2025 12:24

(Alliance News) - Allergy Therapeutics PLC on Monday said talks are underway regarding further financing as it said reduced costs helped trim its half-year loss. Read More

Allergy Therapeutics peanut allergy vaccine trial enters final phase

27th Mar 2025 18:27

(Alliance News) - Allergy Therapeutics PLC on Thursday said its peanut allergy vaccine trial has entered the final treatment phase. Read More

IN BRIEF: Allergy Therapeutics expects annual sales to rise on-year

28th Jan 2025 21:19

Allergy Therapeutics PLC - Sussex, England-based biotechnology company - Expects revenue to rise by 1.1%, or by 4% at constant currency, to GBP34.0 million in the six months ended December from GBP33.6 million a year ago. Sales are expected to continue to grow in the second half of the financial year. Overall, expects sales for the full year ending June 30 to exceed sales in the corresponding period ended June 2024. Reports cash position of GBP21.7 million at the end of December, rising from GBP12.9 million a year ago, following receipt of new GBP20 million five-year term loan. Chief Executive Manuel Llobet says: "We enter 2025 building strong momentum across all aspects of our business. Our return to first-half growth and strengthened position, having secured the Hayfin facility in late 2024, give us the confidence and financial stability to further our ambitious strategy." Read More

UK shareholder meetings calendar - next 7 days

9th Dec 2024 11:30

Read More

IN BRIEF: Allergy Therapeutics treats first patient in allergy trial

27th Nov 2024 16:52

Allergy Therapeutics PLC - Sussex, England-based biotechnology company - Treats its first patient in the third phase of its paediatric trial of Grass Mata MPL. The trial aims to evaluate the long-term efficacy and safety of the drug in treating children with grass pollen allergies. The drug was trialled in adults last year, and showed a "highly statistically significant reduction in the combined symptom and medication score". Grass Mata MPL addresses the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen, and works to modify the body's allergic response in as few as six injections ahead of the allergy season. Read More

See more Allergy Thera. news
FTSE 100 Latest
Value8,745.42
Change26.67

Login to your account

Forgot Password?

Not Registered